Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14957505 | 0.88 | NR1H2 (0.30) | NR1H2NR1H3 | |
| SCHEMBL15302216 | 0.85 | — | — | |
| SCHEMBL73339 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHRL3MBTL1CYP2C19KDM4E | |
| SCHEMBL5491545 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHRL3MBTL1CYP2C19KDM4E | |
| SCHEMBL15302451 | 0.82 | TSHR (0.30) | TSHR | |
| SCHEMBL9715855 | 0.78 | NR1H2 (0.35) | ALDH1A1TSHRL3MBTL1NR1H2NR1H3 | |
| SCHEMBL723613 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHRL3MBTL1CYP2C19HPGD | |
| SCHEMBL536223 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRL3MBTL1CYP2C19HPGD | |
| SCHEMBL296966 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRL3MBTL1CYP2C19HPGD | |
| SCHEMBL7118374 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1CYP2C19IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0361827-A1 | Pyrazole compounds, method for production thereof, use thereof and intermediates for production thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-04-04 | — | — | EP | claimed |
| CN-117891131-A | Hydrophobic low-temperature cured resin composition and preparation method and application thereof | 阜阳欣奕华材料科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-8791221-B2 | Addition-curable metallosiloxane compound | DAICEL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2650319-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | Daicel Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| CN-103249762-A | Addition-curable metallosiloxane compound | DAICEL CORP | 2013-08-14 | — | — | CN | disclosed |
| CN-100427490-C | Process for preparing allyl chlorosilane | HANGZHOU TEACHERS COLLEGE (CN) | 2008-10-22 | — | — | CN | disclosed |
| US-7232799-B2 | Streptogramin derivatives and compositions thereof | AVENTIS PHARMA SA (FR) | 2007-06-19 | — | — | US | disclosed |
| CN-1880321-A | Process for preparing allyl chlorosilane | HANGZHOU TEACHERS COLLEGE (CN) | 2006-12-20 | — | — | CN | disclosed |
| US-20050267181-A1 | Streptogramin derivatives and compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-12-01 | — | — | US | disclosed |
| US-6962901-B2 | Streptogramin derivatives, their preparation and compositions which contain them | AVENTIS PHARMA S.A. (FR) | 2005-11-08 | — | — | US | disclosed |
| US-20030207928-A1 | Streptogramin derivatives, their preparation and compositions which contain them | AVENTIS PHARMA S.A. | 2003-11-06 | — | — | US | disclosed |
| US-6596717-B2 | As antibiotic agent | AVENTIS PHARMA S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20020143041-A1 | Streptogramin derivatives, their preparation and compositions which contain them | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | US | disclosed |
| US-6288066-B1 | ANTIDIABETIC AGENTS; OXIDATION, HYDROLYSIS | AVENTIS PHARMA S.A. (FR) | 2001-09-11 | — | — | US | disclosed |
| EP-0361827-B1 | PYRAZOLE COMPOUNDS, METHOD FOR PRODUCTION THEREOF, USE THEREOF AND INTERMEDIATES FOR PRODUCTION THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5028714-A | Chemical intermediate for fungicide, miticide, insecticide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
| US-4980345-A | INSECTICIDES, ACARICIDES, FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0361827-A1 | Pyrazole compounds, method for production thereof, use thereof and intermediates for production thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207928-A1 | Streptogramin derivatives, their preparation and compositions which contain them | MRPL21, SPG11, STT3B | ALDH1A1 4753/4885TSHR 3551/4885L3MBTL1 4860/4885 |
| US-20020143041-A1 | Streptogramin derivatives, their preparation and compositions which contain them | MRPL21, SPG11, STT3B | ALDH1A1 4753/4885TSHR 3551/4885L3MBTL1 4860/4885 |
| US-20050267181-A1 | Streptogramin derivatives and compositions thereof | SPG11, SRI, BSG | ALDH1A1 4648/4885TSHR 3126/4885L3MBTL1 4837/4885 |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | B2M, MSI2, MNS1 | ALDH1A1 2073/4885TSHR 4702/4885L3MBTL1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.